ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery

How One Tiny Molecule Turned into One Huge Health Breakthrough

Nutrients Boost Stem Cell Function

Humans have three times more brown body fat

B12 Proven Essential for Every Cell

Soy isoflavones may benefit breast cancer patients

How B Vitamins Improve Brain Health, Cognition, Psychiatric Problems and Mood Disorders

Dietary prebiotics improve sleep, buffer impacts of stress, says study

Ylang Ylang Oil Not Only Soothes Your Skin, but Your Mind as Well

Exercises to Help Prevent Urinary Incontinence

 
Print Page
Email Article

Merck Denies Vioxx Linked to Eleven Deaths

  [ 10 votes ]   [ Discuss This Article ]
By Deborah Cooper • www.ProHealth.com • September 19, 2000


Eleven patients using Vioxx have died in Britain according to a UK drug regulatory body, but the drug manufacturer Merck & Co. deny its arthritis drug was linked to the mortalities.

In addition to the deaths the UK’s regulatory bodies, the Medicines Control Agency and the Committee on the Safety of Medicines has received 1,120 reports of adverse effects to rofecoxib, the generic name for Vioxx.

According to the report published in the agency's September newsletter Current Problems, “Gastrointestinal (GI) adverse reactions account for almost half (554) of the reports, of which the majority were nausea, dyspepsia, diarrhea and abdominal pain. However, there have been 68 reports of upper GI perforations, ulcerations and bleeds (PUBs). Forty-four of the patients with PUBs recovered, although five had a fatal outcome.”

It is these five fatalities, along with six other deaths in people with possible cardiac failure and among people with a high risk factor for cardiovascular disease, that has raised the alarm for prescribers and consumers alike.

The other deaths mentioned in the report were part of a total of 192 incidences of suspected cardiovascular reactions, including 15 reports of cardiac failure, 101 reports of edema and 19 reports of palpitations.

Merck & Co., the US drug giant, said that none of the deaths was linked to the medicine. A spokeswoman for the company, Mary Elizabeth Basaman said “There is not a cause and effect. They’re not attributing anything to a specific drug.” Another Merck official, Eve Slater, added, “The report…is no cause for concern.”

The drug maker also pointed out that eleven deaths in a large aging population should not be considered remarkable.

However, the regulatory agency's report concluded with a cautious note. “As with all new drugs, the safety of refocoxib remains under close review.”

An estimated 557,100 prescriptions for Vioxx were dispensed in Britain up to the end of May 2000. The rate of reported adverse reactions is approximately one per 500 prescriptions.

Vioxx is approved in the US and UK as a treatment for osteoarthritis, the most common form of arthritis affecting more than 16 million Americans. Its competitor is another drug also in the same class of non steroidal anti-inflammatory drugs, the Cox-2 inhibitor Celebrex, manufactured by Pharmacia Corp. Last year, Celebrex reached $1.5 billion in sales and Vioxx, launched four months later, garnered $472 million. Both drugs are considered safer and easier to handle than some older arthritis medications such as aspirin.

Rofecoxib (Vioxx) does come with warnings that it is contraindicated in patients with active peptic ulceration or GI bleeding, as well as for patients with severe congestive heart failure. Caution is also urged for users who have a history of cardiac failure, left ventricular dysfunction or hypertension, and in patients with pre-existing edema for any other reason.



Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Mitochondria Ignite™ with NT Factor® Vitamin D3 Extreme™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Prepare Yourself for Cold & Flu Season Prepare Yourself for Cold & Flu Season
Red Yeast Rice - Natural Option for Supporting Healthy Cholesterol Red Yeast Rice - Natural Option for Supporting Healthy Cholesterol
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Top 3 Nutrients to Detox the Liver and Soothe Digestion Top 3 Nutrients to Detox the Liver and Soothe Digestion
How One Tiny Molecule Turned into One Huge Health Breakthrough How One Tiny Molecule Turned into One Huge Health Breakthrough

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map